Curriculum Vitae

INVITED REPRESENTATIONS (selected)

1. Beasley C
   A tale of two profiles: the hemodynamic effects of atomoxetine under clinical observation vs. intensive monitoring
   Cardiac Safety Research Consortium – Pediatric Cardiovascular Safey Drug and Medical Device Development Thinktank. Silver Spring, MD, Dec. 10, 2010.
2. Beasley C
   Are there ways to create robust and informative datasets through pooling?
   Workshop on CNS Clinical Trials: suicidality and data collection  Sponsored by the Institute of Medicine.  Washington, DC, June 16, 2009.
3. Beasley C
   How to characterize the QT effect in the targeted patient population when a TQT study is positive
   DIA Conference: Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding. Arlington, VA, Apr. 12, 2009.
4. Beasley C
   Assessment of fluoxetine and suicide
   Thinktank on Assessment of Treatment-Emergent Suicidality sponsored by Best Practices Project Management, Inc. and Department of Psychiatry, Harvard Medical School.  Washington, DC, Mar 23-24, 2009.
5. Beasley C
   Regulatory, procedural, and statistical considerations in the thorough QT study: the complexity of the design of a thorough QT study
   World Pharmaceutical Congress. Philadelphia, PA, May 12, 2008.
6. Beasley C
   Conduct & Design of a TQT Study
   Keynote address. QT and Drug Development. London, England, Oct. 24, 2007.
7. Beasley C
   Effective strategies for designing thorough QT studies
   eXlpharma webinar. Sept. 27, 2007.
8. Beasley C
   Why we need improved preclinical predictors and human biomarkers for torsades de pointe
   Keynote presentation, Cardiac Safety. World Pharmaceutical Congress. Philadelphia, PA, June 12, 2007.
9. Beasley C
   Is 36,000 ECGs overkill?
   DIA Conference – Challenges and Practical Aspects of Assessing Clinical QT Prolongation / Proarrhythmia Risk and Implications for the Critical Pathway. Washington, DC, May 9, 2006.
10. Beasley C
    Do we need a new ear, a new purse, or both? OR What do we need to more effectively and efficiently confirm the absence of risk of torsades?
    Cardiac Safety and Critical Pathway Initiative Regulatory Think-Tank. Bethesda, MD, Oct. 11, 2005.
11. Beasley C
    Fluoxetine and suicidality revisited
    A Workshop on Antidepressants and suicide.  Sponsored by Department of Psychiatry, Columbia College of Physicians and Surgeons and New York State Psychiatric Institute.  New York, NY. Apr. 19, 2005.
12. Beasley C
    Drug development from the industry perspective: challenges and opportunities
    A Workshop on Clinical Trials in Psychopharmacology. New York, NY, Apr. 12, 2005.
13. Beasley C
    Olanzapine
    British Association for Psychopharmacology Regional Meeting. Guilford, England, Oct. 10, 1997.
14. Beasley C
    Olanzapine: atypical antipsychotic
    American Society of Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, Mar. 21, 1996.
15. Beasley C
    Olanzapine clinical development: molecule to drug candidate
    NCDEU Annual Meeting. Orlando, FL, June 1, 1995.
16. Beasley C
    Clinical trial design in depression and anxiety
    PMA Education and Research Institute Course Drug Development in Depression and Anxiety. Boston, MA, Mar. 15, 1994.
17. Beasley C
    Atypical antipsychotics: What are they?
    Grand Rounds, Cleveland Clinic. Cleveland, OH, Nov. 4, 1993.
18. Beasley C
    Olanzapine
    International Congress on Schizophrenia Research. Colorado Springs, CO, Apr. 20, 1993.
19. Beasley C
    Fluoxetine in tricyclic refractory major depressive disorder
    Second International Conference on Refractory Depression. Amsterdam, The Netherlands, June 26, 1992.
20. Beasley C
    Fluoxetine: significance of plasma concentrations and impact on psychomotor performance
    1992 Annual Lectureship in Forensic Toxicology. Annual meeting of the American Academy of Forensic Sciences. New Orleans, LA, Feb. 21, 1992.
21. Beasley C, Farries D
    Fluoxetine: worldwide suicidality data
    Annual Meeting of the American College of Neuropsychopharmacology  (Study Group). San Juan, PR, Dec. 11, 1991.
22. Beasley C, Farries D
    Strategies to lower placebo response rates in depressed patients in antidepressant trials
    Annual Meeting of the American College of Neuropsychopharmacology (Study Group). San Juan, PR, Dec. 9, 1991.
23. Beasley C, Dornseif B
    Placebo response in depression: associated variables?
    Annual Meeting of the American College of Neuropsychopharmacology(Study Group). Maui, HA, Dec. 13, 1989.
24. Beasley C
    TSH response to TRH and differential drug response in psychosis
    Founder’s Day Resident Award Paper Presentation, Ohio Psychiatric Association. Toledo, OH, Apr. 23, 1988.
25. Beasley C
    Medication response subtyping of psychoses and neuroendocrine correlates
    Indiana University Psychiatric Research Institute Seminar. Indianapolis, IN, Nov. 5, 1987.
26. Beasley C
    Serotonin uptake inhibitors in psychiatry
    Annual Convention of the Central Neuropsychiatric Association. Indianapolis, IN, Oct. 10, 1987.
27. Beasley C
    TSH response to TRH and medication response subtypes of psychoses
    Maurice Levine Essay Award Presentation, Cincinnati Psychiatric Society. Cincinnati, OH, Apr. 15, 1987.
28. Garver D, Beasley C
    Heterogeneity of neuroleptic response in psychosis: implications for subtyping
    Psychiatric Research Society Annual Meeting. Tampa, FL, Apr. 4, 1987.
29. Beasley C, Garver D
    The heterogeneity of schizophrenic illness(es)
    Annual Meeting & Scientific Symposium, Mental Health Association in Ohio. Columbus, OH, Oct. 10, 1986.
30. Beasley C
    The acquisition of procedural knowledge: some linguistic examples
    University of Kentucky Linguistics Circle. Lexington, KY, Apr. 9, 1980.